Regulation of pancreatic physiology by adrenomedullin and its binding protein

Regulatory Peptides

Volumn 112, Issue 1-3, 2003, Pages 121-130

  Zudaire, E ^a   Cuttitta, F ^a   Martinez A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Complement factor H; CRLR; Diabetes; Glucose homeostasis; Insulinoma

Indexed keywords

ADRENOMEDULLIN; ADRENOMEDULLIN RECEPTOR; BINDING PROTEIN; COMPLEMENT FACTOR H; GLUCOSE; MONOCLONAL ANTIBODY;

GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULINOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS DISEASE; PANCREAS ISLET CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0037445889     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(03)00030-2     Document Type: Review

References (107)

1. Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H.et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun. 192(2):1993;553-560.
2. Ishimitsu T., Kojima M., Kangawa K., Hino J., Matsuoka H., Kitamura K.et al. Genomic structure of human adrenomedullin gene. Biochem. Biophys. Res. Commun. 203(1):1994;631-639.
3. Ishimitsu T., Hoyosa K., Tsukada K., Minami H., Ono M., Ohrui M.et al. Chromosomal sublocalization and microsatellite DNA polymorphism of human adrenomedullin gene. Peptides. 22(11):2002;1739-1744.
4. Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides. 22(11):2001;1693-1711.
5. Ohinata K., Inui A., Asakawa A., Yoshikawa M. Novel actions of proadrenomedullin N-terminal 20 peptide (PAMP). Peptides. 22(11):2001;1809-1816.
6. Garayoa M., Martinez A., Lee S., Pio R., An W.G., Neckers L.et al. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol. Endocrinol. 14(6):2000;848-862.
7. Martinez A., Hodge D.L., Garayoa M., Young H.A., Cuttitta F. Alternative splicing of the proadrenomedullin gene results in differential expression of gene products. J. Mol. Endocrinol. 27(1):2001;31-41.
8. Jimenez N., Calvo A., Martinez A., Rosell D., Cuttitta F., Montuenga L.M. Expression of adrenomedullin and proadrenomedullin N-terminal 20 peptide in human and rat prostate. J. Histochem. Cytochem. 47(9):1999;1167-1178.
9. Lopez J., Cuesta N., Martinez A., Montuenga L., Cuttitta F. Proadrenomedullin N-terminal 20 peptide (PAMP) immunoreactivity in vertebrate juxtaglomerular granular cells identified by both light and electron microscopy. Gen. Comp. Endocrinol. 116(2):1999;192-203.
10. Minamino N., Isumi Y., Kangawa K., Kitamura K., Matsuo H. Adrenomedullin production in vascular cells and its function in the vascular wall. Martinez A., Cuttitta F. Adrenomedullin. 1998;79-102 IOS Press, Washington, DC.
11. Martinez A., Miller M.J., Catt K.J., Cuttitta F. Adrenomedullin receptor expression in human lung and in pulmonary tumors. J. Histochem. Cytochem. 45(2):1997;159-164.
12. Martinez A., Miller M.J., Unsworth E.J., Siegfried J.M., Cuttitta F. Expression of adrenomedullin in normal human lung and in pulmonary tumors. Endocrinology. 136(9):1995;4099-4105.
13. Serrano J., Uttenthal L.O., Martinez A., Fernandez A.P., Martinez de Velasco J., Alonso D.et al. Distribution of adrenomedullin-like immunoreactivity in the rat central nervous system by light and electron microscopy. Brain Res. 853(2):2000;245-268.
14. Kapas S., Hinson J.P. Actions of adrenomedullin on the rat adrenal cortex. Endocr. Res. 22(4):1996;861-865.
15. Kapas S., Hinson J.P. Adrenomedullin in the adrenal cortex and medulla. Martinez A., Cuttitta F. Adrenomedullin. 1998;197-206 IOS Press, Amsterdam.
16. Macri C.J., Loup D., McHale M., Jacobs R., Bales L., Sundborg M.et al. Adrenomedullin is widely expressed throughout normal and abnormal reproductive tissue of woman: evidence for cyclic regulation. Martinez A., Cuttitta F. Adrenomedullin. 1998;207-226 IOS Press, Amsterdam.
17. Lopez J., Cuesta N., Cuttitta F., Martinez A. Adrenomedullin in nonmammalian vertebrate pancreas: an immunocytochemical study. Gen. Comp. Endocrinol. 115(3):1999;309-322.
18. Mulder H., Ahren B., Karlsson S., Sundler F. Adrenomedullin: localization in the gastrointestinal tract and effects on insulin secretion. Regul. Pept. 62(2-3):1996;107-112.
19. Kiyomizu A., Kitamura K., Kawamoto M., Eto T. Distribution and molecular forms of adrenomedullin and proadrenomedullin N-terminal 20 peptide in the porcine gastrointestinal tract. J. Gastroenterol. 36(1):2001;18-23.
20. Martinez A., Elsasser T.H., Muro-Cacho C., Moody T.W., Miller M.J., Macri C.J.et al. Expression of adrenomedullin and its receptor in normal and malignant human skin: a potential pluripotent role in the integument. Endocrinology. 138(12):1997;5597-5604.
21. Montuenga L., Martinez A., Miller M.J., Garayoa M., Elsasser T., Cuttitta F. Expression of AM and PAMP in normal adult and developing mammals. Martinez A., Cuttitta F. Adrenomedullin. 1998;49-68 IOS Press, Amsterdam.
22. Ichiki Y., Kitamura K., Kangawa K., Kawamoto M., Matsuo H., Eto T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett. 338(1):1994;6-10.
23. Jahnke G.D., Miller M.J., Martinez A., Montuenga L., Cuttitta F. Adrenomedullin expression in the mouse mammary gland: evidence for the mature form in milk. J. Mol. Endocrinol. 19(3):1997;279-289.
24. Pio R., Martinez A., Elsasser T.H., Cuttitta F. Presence of immunoreactive adrenomedullin in human and bovine milk. Peptides. 21(12):2000;1859-1863.
25. Sato K., Hirata Y., Imai T., Iwashina M., Marumo F. Characterization of immunoreactive adrenomedullin in human plasma and urine. Life Sci. 57(2):1995;189-194.
26. Nagata N., Kato J., Kitamura K., Kawamoto M., Tanaka N., Eto T.et al. Dissociation of adrenomedullin concentrations in plasma and cerebrospinal fluid in pregnant and non-pregnant women. Eur. J. Endocrinol. 139(6):1998;611-614.
27. Takahashi K., Sone M., Satoh F., Murakami O., Totsune K., Tanji H.et al. Presence of adrenomedullin-like immunoreactivity in the human cerebrospinal fluid. Peptides. 18(3):1997;459-461.
28. Allaker R.P., Zihni C., Kapas S. An investigation into the antimicrobial effects of adrenomedullin on members of the skin, oral, respiratory tract and gut microflora. FEMS Immunol. Med. Microbiol. 23(4):1999;289-293.
29. Macri C.J., Martinez A., Moody T.W., Gray K.D., Miller M.J., Gallagher M.et al. Detection of adrenomedullin, a hypotensive peptide, in amniotic fluid and fetal membranes. Am. J. Obstet. Gynecol. 175(4 Pt 1):1996;906-911.
30. Hinson J.P., Kapas S., Smith D.M. Adrenomedullin, a multifunctional regulatory peptide. Endocr. Rev. 21(2):2000;138-167.
31. Lopez J., Martinez A. Cell and molecular biology of the multifunctional peptide, adrenomedullin. Int. Rev. Cyt. 221:2002;1-92.
32. Nikitenko L.L., Smith D.M., Hague S., Wilson C.R., Bicknell R., Rees M.C. Adrenomedullin and the microvasculature. Trends Pharmacol. Sci. 23(3):2002;101-103.
33. Caron K.M., Smithies O. Multiple roles of adrenomedullin revealed by animal models. Microsc. Res. Tech. 57:2002;55-59.
34. Garayoa M., Bodegas E., Cuttitta F., Montuenga L. Adrenomedullin in mammalian embryogenesis. Microsc. Res. Tech. 57:2002;40-54.
35. Montuenga L.M., Martinez A., Miller M.J., Unsworth E.J., Cuttitta F. Expression of adrenomedullin and its receptor during embryogenesis suggests autocrine or paracrine modes of action. Endocrinology. 138(1):1997;440-451.
36. Caron K.M., Smithies O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc. Natl. Acad. Sci. U. S. A. 98(2):2001;615-619.
37. Shindo T., Kurihara Y., Nishimatsu H., Moriyama N., Kakoki M., Wang Y.et al. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation. 104(16):2001;1964-1971.
38. Martinez A., Cuttitta F., Teitelman G. Expression pattern for adrenomedullin during pancreatic development in the rat reveals a common precursor with other endocrine cell types. Cell Tissue Res. 293(1):1998;95-100.
39. Harrison J.K., Barber C.M., Lynch K.R. Molecular cloning of a novel rat G-protein-coupled receptor gene expressed prominently in lung, adrenal, and liver. FEBS Lett. 318(1):1993;17-22.
40. Kapas S., Catt K.J., Clark A.J. Cloning and expression of cDNA encoding a rat adrenomedullin receptor. J. Biol. Chem. 270(43):1995;25344-25347.
41. Eva C., Sprengel R. A novel putative G protein-coupled receptor highly expressed in lung and testis. DNA Cell Biol. 12(5):1993;393-399.
42. Libert F., Parmentier M., Lefort A., Dumont J.E., Vassart G. Complete nucleotide sequence of a putative G protein coupled receptor: RDC1. Nucleic Acids Res. 18(7):1990;1917.
43. Hanze J., Dittrich K., Dotsch J., Rascher W. Molecular cloning of a novel human receptor gene with homology to the rat adrenomedullin receptor and high expression in heart and immune system. Biochem. Biophys. Res. Commun. 240(1):1997;183-188.
44. Kennedy S.P., Sun D., Oleynek J.J., Hoth C.F., Kong J., Hill R.J. Expression of the rat adrenomedullin receptor or a putative human adrenomedullin receptor does not correlate with adrenomedullin binding or functional response. Biochem. Biophys. Res. Commun. 244(3):1998;832-837.
45. Hay D.L., Smith D.M. Adrenomedullin receptors: molecular identity and function. Peptides. 22(11):2001;1753-1763.
46. Muff R., Born J.A., Fischer J.A. Adrenomedullin and related peptides: receptors and accessory proteins. Peptides. 22(11):2001;1765-1772.
47. Marinissen M.J., Gutkind J.S. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol. Sci. 22(7):2001;368-376.
48. Njuki F., Nicholl C.G., Howard A., Mak J.C., Barnes P.J., Girgis S.I.et al. A new calcitonin-receptor-like sequence in rat pulmonary blood vessels. Clin. Sci. (Colch.). 85(4):1993;385-388.
49. Aiyar N., Rand K., Elshourbagy N.A., Zeng Z., Adamou J.E., Bergsma D.J.et al. A cDNA encoding the calcitonin gene-related peptide type 1 receptor. J. Biol. Chem. 271(19):1996;11325-11329.
50. McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N.et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 393(6683):1998;333-339.
51. Miret J.J., Rakhilina L., Silverman L., Oehlen B. Functional expression of heteromeric calcitonin gene-related peptide and adrenomedullin receptors in yeast. J. Biol. Chem. 277(9):2002;6881-6887.
52. Hilairet S., Foord S.M., Marshall F.H., Bouvier M. Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor-like receptor and the receptor activity-modifying proteins. J. Biol. Chem. 276(31):2001;29575-29581.
53. Flahaut M., Rossier B.C., Firsov D. Respective roles of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) in cell surface expression of CRLR/RAMP heterodimeric receptors. J. Biol. Chem. 277(17):2002;14731-14737.
54. Ono Y., Okano I., Kojima M., Okada K., Kangawa K. Decreased gene expression of adrenomedullin receptor in mouse lungs during sepsis. Biochem. Biophys. Res. Commun. 271(1):2000;197-202.
55. Totsune K., Takahashi K., Mackenzie H.S., Murakami O., Arihara Z., Sone M.et al. Increased gene expression of adrenomedullin and adrenomedullin-receptor complexes, receptor-activity modifying protein (RAMP)2 and calcitonin-receptor-like receptor (CRLR) in the hearts of rats with congestive heart failure. Clin. Sci. (Lond.). 99(6):2000;541-546.
56. Nagae T., Mukoyama M., Sugawara A., Mori K., Yahata K., Kasahara M.et al. Rat receptor-activity-modifying proteins (RAMPs) for adrenomedullin/CGRP receptor: cloning and upregulation in obstructive nephropathy. Biochem. Biophys. Res. Commun. 270(1):2000;89-93.
57. Mukoyama M., Sugawara A., Nagae T., Mori K., Murabe H., Itoh H.et al. Role of adrenomedullin and its receptor system in renal pathophysiology. Peptides. 22(11):2001;1925-1931.
58. Qing X., Svaren J., Keith I.M. mRNA expression of novel CGRP1 receptors and their activity-modifying proteins in hypoxic rat lung. Am. J. Physiol., Lung Cell. Mol. Physiol. 280(3):2001;L547-L554.
59. Kitamuro T., Takahashi K., Totsune K., Nakayama M., Murakami O., Hida W.et al. Differential expression of adrenomedullin and its receptor component, receptor activity modifying protein (RAMP) 2 during hypoxia in cultured human neuroblastoma cells. Peptides. 22(11):2001;1795-1801.
60. Prado M.A., Evans-Bain B., Oliver K.R., Dickerson I.M. The role of the CGRP-receptor component protein (RCP) in adrenomedullin receptor signal transduction. Peptides. 22(11):2001;1773-1782.
61. Muff R., Born W., Fischer J.A. Calcitonin, calcitonin gene-related peptide, adrenomedullin and amylin: homologous peptides, separate receptors and overlapping biological actions. Eur. J. Endocrinol. 133(1):1995;17-20.
62. Poyner D.R. Molecular pharmacology of receptors for calcitonin-gene-related peptide, amylin and adrenomedullin. Biochem. Soc. Trans. 25(3):1997;1032-1036.
63. Coppock H.A., Owji A.A., Bloom S.R., Smith D.M. A rat skeletal muscle cell line (L6) expresses specific adrenomedullin binding sites but activates adenylate cyclase via calcitonin gene-related peptide receptors. Biochem. J. 318(Pt 1):1996;241-245.
64. Coppock H.A., Owji A.A., Austin C., Upton P.D., Jackson M.L., Gardiner J.V.et al. Rat-2 fibroblasts express specific adrenomedullin receptors, but not calcitonin-gene-related-peptide receptors, which mediate increased intracellular cAMP and inhibit mitogen-activated protein kinase activity. Biochem. J. 338(Pt 1):1999;15-22.
65. Hayakawa H., Hirata Y., Kakoki M., Suzuki Y., Nishimatsu H., Nagata D.et al. Role of nitric oxide-cGMP pathway in adrenomedullin-induced vasodilation in the rat. Hypertension. 33(2):1999;689-693.
66. Hirata Y., Hayakawa H., Suzuki Y., Suzuki E., Ikenouchi H., Kohmoto O.et al. Mechanisms of adrenomedullin-induced vasodilation in the rat kidney. Hypertension. 25(4 Pt 2):1995;790-795.
67. Feng C.J., Kang B., Kaye A.D., Kadowitz P.J., Nossaman B.D. L-NAME modulates responses to adrenomedullin in the hindquarters vascular bed of the rat. Life Sci. 55(22):1994;L433-L438.
68. Miura K., Ebara T., Okumura M., Matsuura T., Kim S., Yukimura T.et al. Attenuation of adrenomedullin-induced renal vasodilatation by NG-nitro L-arginine but not glibenclamide. Br. J. Pharmacol. 115(6):1995;917-924.
69. Cuttitta F., Montuenga L.M., Garayoa M., Pio R., Miller M.J., Walsh T.et al. The role of adrenomedullin as a growth regulatory peptide in the normal and malignant setting. J. Anim. Sci. 77(Suppl. 3):1999;55-69.
70. Haneda M., Araki S., Sugimoto T., Togawa M., Koya D., Kikkawa R. Differential inhibition of mesangial MAP kinase cascade by cyclic nucleotides. Kidney Int. 50(2):1996;384-391.
71. Chini E.N., Choi E., Grande J.P., Burnett J.C., Dousa T.P. Adrenomedullin suppresses mitogenesis in rat mesangial cells via cAMP pathway. Biochem. Biophys. Res. Commun. 215(3):1995;868-873.
72. Togawa M., Haneda M., Araki S., Sugimoto T., Isono M., Hidaka H.et al. Beraprost sodium, an analogue of prostacyclin, induces the expression of mitogen-activated protein kinase phosphatase and inhibits the proliferation of cultured mesangial cells. Eur. J. Pharmacol. 336(2-3):1997;291-294.
73. Iwasaki H., Eguchi S., Shichiri M., Marumo F., Hirata Y. Adrenomedullin as a novel growth-promoting factor for cultured vascular smooth muscle cells: role of tyrosine kinase-mediated mitogen-activated protein kinase activation. Endocrinology. 139(8):1998;3432-3441.
74. Sakai K., Saito K., Ishizuka N. Adrenomedullin synergistically interacts with endogenous vasodilators in rats: a possible role of K(ATP) channels. Eur. J. Pharmacol. 359(2-3):1998;151-159.
75. Elsasser T.H., Kahl S., Martinez A., Montuenga L.M., Pio R., Cuttitta F. Adrenomedullin binding protein in the plasma of multiple species: characterization by radioligand blotting. Endocrinology. 140(10):1999;4908-4911.
76. Pio R., Martinez A., Unsworth E.J., Kowalak J.A., Bengoechea J.A., Zipfel P.F.et al. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J. Biol. Chem. 276(15):2001;12292-12300.
77. Pio R., Elsasser T., Martinez A., Cuttitta F. Identification, characterization, and physiological actions of factor H as an adrenomedullin binding protein present in human plasma. Microsc. Res. Tech. 57:2002;23-27.
78. Pangburn M.K., Muller-Eberhard H.J. Kinetic and thermodynamic analysis of the control of C3b by the complement regulatory proteins factors H and I. Biochemistry. 22(1):1983;178-185.
79. Martinez A., Weaver C., Lopez J., Bhathena S.J., Elsasser T.H., Miller M.J.et al. Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Endocrinology. 137(6):1996;2626-2632.
80. Martinez A., Kapas S., Miller M.J., Ward Y., Cuttitta F. Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic beta-cells. Endocrinology. 141(1):2000;406-411.
81. Martinez A., Pio R., Lopez J., Cuttitta F. Expression of the adrenomedullin binding protein, complement factor H, in the pancreas and its physiological impact on insulin secretion. J. Endocrinol. 170(3):2001;503-511.
82. Fujimura M., Greeley G.H. Jr., Hancock M.B., Alwmark A., Santos A., Cooper C.W.et al. Colocalization of calcitonin gene-related peptide and somatostatin in pancreatic islet cells and inhibition of insulin secretion by calcitonin gene-related peptide in the rat. Pancreas. 3(1):1988;49-52.
83. Tsuchida T., Ohnishi H., Tanaka Y., Mine T., Fujita T. Inhibition of stimulated amylase secretion by adrenomedullin in rat pancreatic acini. Endocrinology. 140(2):1999;865-870.
84. Ruzicska E., Toth M., Tulassay Z., Somogyi A. Adrenomedullin and diabetes mellitus. Diabetes Metab. Res. Rev. 17(5):2001;321-329.
85. Zudaire E., Cuttitta F., Martinez A. Adrenomedullin, pancreatic physiology and diabetes. Pandalai S.G. Recent Research Developments in Endocrinology. 2001;37-54 Transworld Research Network, India.
86. Sowers J.R., Williams M., Epstein M., Bakris G. Hypertension in patients with diabetes. Strategies for drug therapy to reduce complications. Postgrad. Med. 2000;107(4):47-54, 60.
87. Wu J.T. Review of diabetes: identification of markers for early detection, glycemic control, and monitoring clinical complications. J. Clin. Lab. Anal. 7(5):1993;293-300.
88. Tisch R., McDevitt H. Insulin-dependent diabetes mellitus. Cell. 85(3):1996;291-297.
89. Gale E.A. The discovery of type 1 diabetes. Diabetes. 50(2):2001;217-226.
90. Ward W.K., Johnston C.L., Beard J.C., Benedetti T.J., Halter J.B., Porte D. Jr. Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes. 34(9):1985;861-869.
91. Garcia-Unzueta M.T., Montalban C., Pesquera C., Berrazueta J.R., Amado J.A. Plasma adrenomedullin levels in type 1 diabetes. Relationship with clinical parameters. Diabetes Care. 21(6):1998;999-1003.
92. Hirayama N., Kitamura K., Imamura T., Kato J., Koiwaya Y., Eto T. Secretion and clearance of the mature form of adrenomedullin in humans. Life Sci. 64(26):1999;2505-2509.
93. Hayashi M., Shimosawa T., Isaka M., Yamada S., Fujita R., Fujita T. Plasma adrenomedullin in diabetes. Lancet. 350(9089):1997;1449-1450.
94. Nakamura T., Honda K., Ishikawa S., Kitamura K., Eto T., Saito T. Plasma adrenomedullin levels in patients with non-insulin dependent diabetes mellitus: close relationships with diabetic complications. Endocr. J. 45(2):1998;241-246.
95. Martinez A., Elsasser T.H., Bhathena S.J., Pio R., Buchanan T.A., Macri C.J.et al. Is adrenomedullin a causal agent in some cases of type 2 diabetes? Peptides. 20(12):1999;1471-1478.
96. Di Iorio R., Marinoni E., Letizia C., Villaccio B., Alberini A., Cosmi E.V. Adrenomedullin production is increased in normal human pregnancy. Eur. J. Endocrinol. 140(3):1999;201-206.
97. Buchanan T.A. Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J. Clin. Endocrinol. Metab. 86(3):2001;989-993.
98. Greenhouse D.D., Michaelis O.E., McCune S.A. Development of corpulent rat strains. Shafrir D. Frontiers in diabetes research: lessons from animal diabetes. 1990;375-377 Smith-Gordon, London.
99. Kinoshita H., Kato K., Kuroki M., Nakamura S., Kitamura K., Hisanaga S.et al. Plasma adrenomedullin levels in patients with diabetes. Diabetes Care. 23(2):2000;253-254.
100. Kinoshita H., Fujimoto S., Kitamura K., Matsuura Y., Uezono S., Hisanaga S.et al. Increased plasma levels of mature adrenomedullin in chronic glomerulonephritis. Nephron. 86(3):2000;333-338.
101. Eto T., Washimine H., Kato J., Kitamura K., Yamamoto Y. Adrenomedullin and proadrenomedullin N-terminal 20 peptide in impaired renal function. Kidney Int., Suppl. 55:1996;S148-S149.
102. Shimosawa T., Ogihara T., Asano T., Wang D., Takahashi K., Ando K.et al. Decreased expression level of adrenomedullin induces obesity and insulin-resistant diabetes. The Endocrine Society's 83rd Annual Meeting, Denver, CO. 2001;69 The Endocrine Society Press, Bethesda, MD.
103. Katsuki A., Sumida Y., Gabazza E.C., Murashima S., Urakawa H., Morioka K.et al. Acute hyperinsulinemia is associated with increased circulating levels of adrenomedullin in patients with type 2 diabetes mellitus. Eur. J. Endocrinol. 147(1):2002;71-75.
104. Letizia C., Tamburrano G., Alo P., Paoloni A., Caliumi C., Marinoni E.et al. Adrenomedullin, a new peptide, in patients with insulinoma. Eur. J. Endocrinol. 144(5):2001;517-520.
105. Miller M.J., Martinez A., Unsworth E.J., Thiele C.J., Moody T.W., Elsasser T.et al. Adrenomedullin expression in human tumor cell lines. It's potential role as an autocrine growth factor. J. Biol. Chem. 271(38):1996;23345-23351.
106. Letizia C., Di Iorio R., De Toma G., Marinoni E., Cerci S., Celi M.et al. Circulating adrenomedullin is increased in patients with corticotropin-dependent Cushing's syndrome due to pituitary adenoma. Metabolism. 49(6):2000;760-763.
107. Aiyar N., Daines R.A., Disa J., Chambers P.A., Sauermelch C.F., Quiniou M.et al. Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. J. Pharmacol. Exp. Ther. 296(3):2001;768-775.